Intellia Therapeutics Stock Options

NTLA Stock  USD 9.31  0.31  3.44%   
Intellia Therapeutics' latest option contracts expiring on May 16th 2025 are carrying combined implied volatility of 1.52. The Intellia Therapeutics option chain provides detailed quote and price information for the current Intellia Therapeutics option contracts. It shows all of Intellia Therapeutics' listed puts, calls, expiration dates, strike prices, and other pricing information.

In The Money vs. Out of Money Option Contracts on Intellia Therapeutics

Analyzing Intellia Therapeutics' in-the-money options over time can help investors to take a profitable long position in Intellia Therapeutics regardless of its overall volatility. This is especially true when Intellia Therapeutics' options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Intellia Therapeutics' options could be used as guardians of the underlying stock as they move almost dollar for dollar with Intellia Therapeutics' stock while costing only a fraction of its price.
Intellia Therapeutics' stock options are financial instruments that give investors the right to buy or sell shares of Intellia Therapeutics common stock at a specified price for a given time period. Generally speaking, an option to purchase or sell Intellia stock makes it part of the underlying stock when the option's price is tied to the movement of the underlying stock. If Intellia Therapeutics' stock price goes up or down, the stock options follow.
At present, Intellia Therapeutics' Other Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Stock Based Compensation is expected to grow to about 161.9 M, whereas Total Stockholder Equity is forecasted to decline to about 585.8 M.

Intellia Therapeutics In The Money Call Balance

When Intellia Therapeutics' strike price is surpassing the current stock price, the option contract against Intellia Therapeutics stock is said to be in the money. When it comes to buying Intellia Therapeutics' options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Intellia Therapeutics are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.

Intellia Current Options Market Mood

Intellia Therapeutics' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Intellia Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.

Put-to-Call Volume

Unfortunately, most Intellia Therapeutics' options investors are not very successful. Intellia Therapeutics' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.

Rule 16 of the current Intellia contract

Base on the Rule 16, the options market is currently suggesting that Intellia Therapeutics will have an average daily up or down price movement of about 0.095% per day over the life of the 2025-05-16 option contract. With Intellia Therapeutics trading at USD 9.31, that is roughly USD 0.008845. If you think that the market is fully incorporating Intellia Therapeutics' daily price movement you should consider buying Intellia Therapeutics options at the current volatility level of 1.52%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
  
Purchasing Intellia Therapeutics options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Intellia calls. Remember, the seller must deliver Intellia Therapeutics stock to the call owner when a call is exercised.

Intellia Therapeutics Option Chain

When Intellia Therapeutics' strike price is surpassing the current stock price, the option contract against Intellia Therapeutics stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Intellia Therapeutics' option chain is a display of a range of information that helps investors for ways to trade options on Intellia. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Intellia. It also shows strike prices and maturity days for a Intellia Therapeutics against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone.
Open IntStrike PriceCurrent SpreadLast Price
Call
NTLA250516C00017500017.50.0 - 0.150.15Out
Call
NTLA250516C00015000015.00.0 - 0.950.95Out
Call
NTLA250516C00012500012.50.2 - 0.80.3Out
Call
NTLA250516C000100002110.00.65 - 0.90.94Out
Call
NTLA250516C0000750017.51.25 - 2.151.83In
Call
NTLA250516C0000500005.01.5 - 5.11.5In
Call
NTLA250516C0000250002.54.4 - 9.04.4In
 Put
NTLA250516P00017500017.57.0 - 9.77.0In
 Put
NTLA250516P00015000015.05.0 - 6.45.0In
 Put
NTLA250516P00012500012.51.5 - 5.81.5In
 Put
NTLA250516P00010000010.00.75 - 3.10.75In
 Put
NTLA250516P0000750007.50.0 - 0.650.65Out
 Put
NTLA250516P0000500005.00.0 - 1.251.25Out
 Put
NTLA250516P0000250002.50.0 - 1.251.25Out

Intellia Total Stockholder Equity

Total Stockholder Equity

585.82 Million

At present, Intellia Therapeutics' Total Stockholder Equity is projected to increase significantly based on the last few years of reporting.

Intellia Therapeutics Corporate Management

JD EsqGeneral VPProfile
Jennifer DoudnaFounder BoardProfile
Derek HicksExecutive OfficerProfile
Andrew MayFounder BoardProfile
When determining whether Intellia Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Intellia Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Intellia Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Intellia Therapeutics Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Intellia Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.
You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intellia Therapeutics. If investors know Intellia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intellia Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.25)
Revenue Per Share
0.586
Quarterly Revenue Growth
(0.24)
Return On Assets
(0.27)
Return On Equity
(0.54)
The market value of Intellia Therapeutics is measured differently than its book value, which is the value of Intellia that is recorded on the company's balance sheet. Investors also form their own opinion of Intellia Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Intellia Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intellia Therapeutics' market value can be influenced by many factors that don't directly affect Intellia Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intellia Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Intellia Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intellia Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.